Breaking News

Lundbeck, Otsuka Alliance Adds Alzheimer's Drug

March 26, 2013

To co-develop and commercialize Lu AE58054

H. Lundbeck and Otsuka Pharmaceutical have entered a license and development agreement for Lu AE58054, a selective 5HT6 receptor antagonist in Phase III development for the treatment of Alzheimer's disease. Lundbeck will grant Otsuka co-development and co-commercialization rights to Lu AE58054 in the U.S., Canada, East Asia, and major European and Nordic countries.
 
Lundbeck will receive an initial payment of $150 million and both companies will share the sales, development, and commercialization costs. Lundbeck is also entitled to as much as $675 million in regulatory and sales milestones.
 
Taro Iwamoto, president and representative director of Otsuka Pharmaceutical, said, "The global collaboration between Otsuka and Lundbeck continues to grow stronger with the addition of Lu AE58054. Not only does the product further enhance the synergy between the companies as we work together to bring to the market solutions for better health, Lu AE58054 is a potentially promising development in a very difficult disease area."
 
Ulf Wiinberg, president and chief executive officer of Lundbeck, said, "There is a serious, global, unmet medical need regarding treatments for Alzheimer's disease in aging populations. Together, Otsuka and Lundbeck with their development capabilities, commercial experience and geographical reach will provide a solid foundation in the development of Lu AE58054."

Related Contract Manufacturing:

blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent